TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18952347

Group type: EXPERIMENTAL
Intervention: LTS-D
Number of subjects: 200

Group type: COMPARATOR
Intervention: I-gel
Number of subjects: 200
Study: 17373900

Group type: EXPERIMENTAL
Intervention: Trastuzumab (humanised monoclonal antibody to the HER2 receptor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy and endocrine therapies
Number of subjects: 0
Study: 15292325

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily for nine months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control data (not specified)
Number of subjects: 10
Study: 11903176

Group type: EXPERIMENTAL
Intervention: Digital luminescence radiography (DLR)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional film screen radiography
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both DLR and conventional film screen radiography
Number of subjects: 210
Study: 9034949

Group type: EXPERIMENTAL
Intervention: Self‐administered, structured, previsit questionnaire combined with a postvisit questionnaire
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Interviewer‐administered, semistructured, previsit interview combined with a postvisit questionnaire
Number of subjects: 318

Group type: COMPARATOR
Intervention: Postvisit questionnaire only
Number of subjects: 318
Study: 8201487

Group type: EXPERIMENTAL
Intervention: Beractant (Survanta)
Number of subjects: 1228
Study: 3661954

Group type: EXPERIMENTAL
Intervention: Pindolol 0.5 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pindolol 1.0 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pindolol 2.0 micrograms/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no pindolol)
Number of subjects: 40
Study: 31837032

Group type: EXPERIMENTAL
Intervention: Text message sent after donation
Number of subjects: 20365

Group type: EXPERIMENTAL
Intervention: Text message sent in the evening
Number of subjects: 20365

Group type: EXPERIMENTAL
Intervention: Text message effect on whole blood donors
Number of subjects: 20365

Group type: EXPERIMENTAL
Intervention: Text message effect on plasma donors
Number of subjects: 20365
Study: 31328432

Group type: EXPERIMENTAL
Intervention: Assisted reproductive technologies (ART) and non-IVF fertility treatments (NIFTs)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (infants with PVD but without ART/NIFT)
Number of subjects: 159
Study: 27999970

Group type: EXPERIMENTAL
Intervention: Oral 30% glucose solution (2 ml/3 kg doses)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intravenous midazolam (0.1 mg/kg with 0.05 mg/kg repetition)
Number of subjects: 112
Study: 26356162

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (intravenously in dose 20 ml in 100 ml of physiological solution, 5 days a week, during 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard neurorehabilitation measures
Number of subjects: 60
Study: 23368405

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 208

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 208
Study: 20488830

Group type: EXPERIMENTAL
Intervention: 15 g glucose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 60 g glucose
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0 g glucose
Number of subjects: 30
Study: 19474688

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Bisoprolol-Control
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Fluvastatin-Control
Number of subjects: 1066
Study: 16959149

Group type: EXPERIMENTAL
Intervention: Combined treatment (Group A)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Fluid replacement only (Group B)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 600
Study: 15040556

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine (SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulphadoxine‐pyrimethamine (AQ + SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artesunate + Sulphadoxine‐pyrimethamine (AR + SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQ + AR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies (AQ + SP, AR + SP, AQ + AR)
Number of subjects: 0
Study: 12194076

Group type: EXPERIMENTAL
Intervention: 0.1% (w/v) sodium hyaluronate (HA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 1.4% (w/v) polyvinyl alcohol
Number of subjects: 39
Study: 9476988

Group type: EXPERIMENTAL
Intervention: Marijuana with long breath-holding duration
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Marijuana with short breath-holding duration
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Breath-holding duration (long vs short)
Number of subjects: 55
Study: 8585876

Group type: EXPERIMENTAL
Intervention: Amtolmetineguacil 600 mg by os twice daily for the first two days followed by 600 mg once daily for 19 days (Group A1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amtolmetineguacil 600 mg twice daily for 21 days (Group A2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: diclofenac 50 mg twice daily by os for 21 days (Group V)
Number of subjects: 30
Study: 2551976

Group type: EXPERIMENTAL
Intervention: rIFN-beta ser nasal drops (9 X 10(6) units) for 4 weeks
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: rIFN-beta ser nasal drops (24 X 10(6) units) for 25 days
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 319973

Group type: EXPERIMENTAL
Intervention: Cytarabine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 31525515

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 338477
Study: 31076942

Group type: EXPERIMENTAL
Intervention: Concentrated fish oil only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Concentrated fish oil in combination with evening primrose oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group without supplementation
Number of subjects: 60
Study: 29306239

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 0
Study: 25524913

Group type: EXPERIMENTAL
Intervention: 10% Intralipid at 100 mL/h
Number of subjects: 7

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 7
Study: 23483989

Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (standard hypocaloric diet)
Number of subjects: 8
Study: 21226576

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 19528363

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 720

Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 720
Study: 17309405

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART) with at least three effective ARVs from at least two different drug classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence to drug therapy greater than 95%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy, two-drug combinations, sequential ARVs, drug cycling, and treatment interruptions
Number of subjects: 0
Study: 15529346

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 10647530

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study: 9370502

Group type: EXPERIMENTAL
Intervention: Peer assessments by geriatricians and geriatric nurse practitioners
Number of subjects: 313

Group type: COMPARATOR
Intervention: Process measures assessed by geriatricians and geriatric nurse practitioners
Number of subjects: 313
Study: 1552038

Group type: EXPERIMENTAL
Intervention: IMI plus ALP
Number of subjects: 48

Group type: COMPARATOR
Intervention: IMI plus placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: IMI alone
Number of subjects: 48
Study: 4009919

Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids‐630 mOsmol/liter
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids/fat emulsion‐706 mOsmol/liter
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids‐882 mOsmol/liter
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dextrose/amino acids/fat emulsion‐983 mOsmol/liter
Number of subjects: 80

Group type: COMPARATOR
Intervention: Concurrent infusion with 20% fat emulsion
Number of subjects: 80
Study: 31220146

Group type: EXPERIMENTAL
Intervention: Telemonitoring follow-ups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hospital monitoring follow-ups
Number of subjects: 50
Study: 28878035

Group type: EXPERIMENTAL
Intervention: Standard regimen (3 × 500 mg Ca/d)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Low-dose regimen (2 × 500 mg Ca/d)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 990
Study: 24493560

Group type: EXPERIMENTAL
Intervention: Total facial nerve decompression (surgery group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisolone (control group)
Number of subjects: 24
Study: 23398636

Group type: EXPERIMENTAL
Intervention: Standard diet + 6 × 60 ml/day of Pro-Cal (60 ml = 200 kcal + 4 g protein)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard diet alone
Number of subjects: 55
Study: 21311842

Group type: EXPERIMENTAL
Intervention: Care provided by a hospital-based specialised asthma nurse
Number of subjects: 107

Group type: COMPARATOR
Intervention: General practitioner (GP) care
Number of subjects: 107

Group type: COMPARATOR
Intervention: Paediatrician care
Number of subjects: 107

Group type: COMPARATOR
Intervention: Specialised asthma nurse care
Number of subjects: 107
Study: 19845100

Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 2.5% plus prilocaine 2.5%) applied daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Methylprednisolone acetate 40 mg injection
Number of subjects: 65
Study: 16757756

Group type: EXPERIMENTAL
Intervention: Augmentation with porcine small intestine mucosa
Number of subjects: 30

Group type: COMPARATOR
Intervention: No augmentation (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Healed repair
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Failed repair
Number of subjects: 30
Study: 15004874

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg qd) for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (12 children aged 11 to 15 with no medical or psychiatric illnesses)
Number of subjects: 18
Study: 11765381

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention
Number of subjects: 17
Study: 9262274

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA) with fentanyl
Number of subjects: 81

Group type: COMPARATOR
Intervention: Physician-administered fentanyl
Number of subjects: 81
Study: 8418715

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 143

Group type: COMPARATOR
Intervention: Inhaled anesthetics
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study: 3535594

Group type: EXPERIMENTAL
Intervention: RHZ regimen (isoniazid and rifampin with pyrazinamide)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: RHE regimen (isoniazid and rifampin with ethambutol)
Number of subjects: 358

Group type: COMPARATOR
Intervention: SHE regimen (streptomycin, isoniazid, and ethambutol for 6 months followed by isoniazid and ethambutol for an additional 6 months)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 358
Study: 2786899

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 110
Study: 30025665

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 50
Study: 29041941

Group type: EXPERIMENTAL
Intervention: Komboni Housewives intervention (community events, health clinics, radio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Komboni Housewives intervention
Number of subjects: 0
Study: 25319879

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with defibrillator (CRT-D)
Number of subjects: 97
Study: 23336504

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) intervention with Standard Health Care Advice (SHCA)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Standard Health Care Advice (SHCA)
Number of subjects: 510
Study: 21659318

Group type: EXPERIMENTAL
Intervention: Decoupling (DC) technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 72
Study: 18042987

Group type: EXPERIMENTAL
Intervention: 500‐microg F/g (NaF) dentifrice
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1,100‐microg F/g dentifrice
Number of subjects: 120
Study: 16209659

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.6 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12547992

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg x kg(-1) x min(-1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 15
Study: 11137410

Group type: EXPERIMENTAL
Intervention: New intubation method with TV monitoring
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional intubation using rigid laryngoscope
Number of subjects: 90
Study: 8659651

Group type: EXPERIMENTAL
Intervention: Saving Lives Program cities
Number of subjects: 54577
Study: 1390375

Group type: EXPERIMENTAL
Intervention: 0.5mg intrathecal morphine with 3 mls of 0.5% intrathecal bupivacine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 3 mls of 0.5% bupivacine with normal saline
Number of subjects: 24
Study: 4005097

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of blood glucose concentration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Frequent intermittent sampling
Number of subjects: 12
Study: 30079637

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) + 5000 ppm sodium fluoride (GLASER)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (laser tip without emission of light) + 5000 ppm sodium fluoride (GPLACEBO)
Number of subjects: 25
Study: 27212226

Group type: EXPERIMENTAL
Intervention: Transdiagnostic group cognitive behavioral therapy (TGCBT) for anxiety over 12 weeks
Number of subjects: 151
Study: 25016974

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy
Number of subjects: 416

Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 416
Study: 22873492

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Sodium benzoate
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid vs Sodium benzoate
Number of subjects: 89
Study: 21049208

Group type: EXPERIMENTAL
Intervention: Group PK (0.15 mg/kg ketamine + 80 ml 0.5% prilocaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group P (80 ml 0.5% prilocaine)
Number of subjects: 40
Study: 18211452

Group type: EXPERIMENTAL
Intervention: Video Laryngoscope
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard Macintosh Laryngoscope
Number of subjects: 49
Study: 15816475

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b/ribavirin combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon alpha-2b monotherapy
Number of subjects: 0
Study: 11443628

Group type: EXPERIMENTAL
Intervention: Infusional cyclophosphamide (187.5 mg/m² per day), doxorubicin (12.5 mg/m² per day), and etoposide (60 mg/m² per day) administered as second-line chemotherapy for 96 hours continuous intravenous infusion.
Number of subjects: 40
Study: 10078811

Group type: EXPERIMENTAL
Intervention: Postischaemic cases (survived cardiac arrest)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control cases (neurologically healthy individuals who died following an accident)
Number of subjects: 3
Study: 8079928

Group type: EXPERIMENTAL
Intervention: Cimetidine plus amoxycillin (500 mg three times a day for 2 weeks) and metronidazole (250 mg three times a day for 2 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg at night for 4 weeks)
Number of subjects: 48
Study: 2680816

Group type: EXPERIMENTAL
Intervention: Cop 1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 786681

Group type: EXPERIMENTAL
Intervention: Intravenous atropine sulphate (0.25, 0.40, 0.75 and 1.50 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravenous atropine methylnitrate (0.08, 0.13 and 0.25 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72
Study: 31976794

Group type: EXPERIMENTAL
Intervention: Military families with 1 ACE
Number of subjects: 5336

Group type: EXPERIMENTAL
Intervention: Military families with 2 ACEs
Number of subjects: 5336

Group type: EXPERIMENTAL
Intervention: Military families with 3-6 ACEs
Number of subjects: 5336

Group type: EXPERIMENTAL
Intervention: Military families attempting suicide
Number of subjects: 5336
Study: 30755234

Group type: EXPERIMENTAL
Intervention: Chocolate Milk (CM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Carbohydrate supplements (CHO)
Number of subjects: 103
Study: 27436450

Group type: EXPERIMENTAL
Intervention: GPS needle-tracking system
Number of subjects: 220

Group type: COMPARATOR
Intervention: Multiplanar ultrasound system
Number of subjects: 220

Group type: COMPARATOR
Intervention: 2D imaging
Number of subjects: 220
Study: 26913493

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis Bb12 (ATCC 27536) chewing gum
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus LGG (ATCC 53103), Bifidobacterium longum 46 (DSM 14583) and Bifidobacterium longum 2C (DSM 14579) chewing gum
Number of subjects: 54
Study: 24103190

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 327

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 327
Study: 22322458

Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 140
Study: 19569007

Group type: EXPERIMENTAL
Intervention: Resistance training (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study: 17590218

Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg twice a day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Celecoxib (200 mg once a day)
Number of subjects: 44
Study: 14733608

Group type: EXPERIMENTAL
Intervention: IVIg plus IFNalpha (400 mg/kg each day for 5 days, then 3 MUI of leucocyte IFNalpha three times a week)
Number of subjects: 42

Group type: COMPARATOR
Intervention: IFNalpha alone (physiological solution followed by leucocyte IFNalpha three times a week for 6 months)
Number of subjects: 42
Study: 11669086

Group type: EXPERIMENTAL
Intervention: Olanzapine (20-40 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 9520070

Group type: EXPERIMENTAL
Intervention: PSP cases (n=11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diseases (Machado‐Joseph disease and DRPLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 8209935

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with ulcer excision
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Partial gastrectomy with gastroduodenostomy
Number of subjects: 30
Study: 2682926

Group type: EXPERIMENTAL
Intervention: Prophylactic neck dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic neck dissection
Number of subjects: 0
Study: 1180024

Group type: EXPERIMENTAL
Intervention: Operated group (surgery)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Non-operated group (conservative treatment)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Doubtful group (random selection for surgery or not)
Number of subjects: 280
Study: 31075442

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (2 L in divided doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg oral)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (in patients with LQTS)
Number of subjects: 40
Study: 28545407

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 315

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 315
Study: 25921980

Group type: EXPERIMENTAL
Intervention: High depression scores
Number of subjects: 166

Group type: COMPARATOR
Intervention: Low depression scores
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Depression score
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Positive problem orientation
Number of subjects: 166
Study: 23575965

Group type: EXPERIMENTAL
Intervention: Pasireotide (600 μg or 900 μg) subcutaneously twice daily for 3 months
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: CushingQOL questionnaire self-administered at baseline, month 3, month 6, and month 12
Number of subjects: 162
Study: 21354671

Group type: EXPERIMENTAL
Intervention: Healthcare education program (personalized information by a trained nurse and written leaflets)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 996
Study: 19711606

Group type: EXPERIMENTAL
Intervention: Pulsonic toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sonicare FlexCare toothbrush
Number of subjects: 0
Study: 17403842

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.89 mg/kg over 10 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 70